Statin escape phenomenon: Fact or fiction?

Fotios Barkas, Moses Elisaf, Eleftherios Klouras, Theodora Dimitriou, Nikolaos Tentolouris, Evangelos Liberopoulos

Statin escape phenomenon was defined as an increase in low-density lipoprotein cholesterol (LDL-C) levels at the most recent visit by > 10% compared with the value at 6 mo following initiation of statin treatment.

Of 181 eligible subjects, 31% exhibited the statin escape phenomenon. No major differences regarding baseline characteristics were found between statin escapers and non-statin escapers. Both escapers and non-escapers had similar baseline LDL-C levels [174 (152-189) and 177 (152-205) mg/dL, respectively]. In comparison with non-escapers, statin escapers demonstrated lower LDL-C levels at 6 mo after treatment initiation [88 (78-97) mg/dL, P < 0.05], but higher levels at the most recent visit [103 (96-118) mg/dL vs 94 (79-114) mg/dL, P < 0.05].

These data confirm the existence of an escape phenomenon among statin-treated individuals. The clinical significance of this phenomenon remains uncertain.
Key words: Statin; Escape; Cholesterol

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This was a retrospective study aiming to evaluate the presence of the so called “statin escape” phenomenon among hyperlipidemic subjects attending a lipid clinic and elucidate any potential confounding factors. This study confirms the limited bibliography reporting on statin escape phenomenon and its quite high prevalence. However, due to the small number of eligible participants, we were not able to identify potential predictors for the statin-escape phenomenon or establish an association between statin escape and incidence of cardiovascular disease. In this context, further investigation on the underlying pathophysiology of this phenomenon and its potential clinical ramifications is required.

Barkas F, Elisaf M, Klouras E, Dimitriou T, Tentolouris N, Liberopoulos E. Statin escape phenomenon: Fact or fiction? World J Exp Med 2017; 7(1): 25-30 Available from: URL: http://www.wjgnet.com/2220-315X/full/v7/i1/25.htm DOI: http://dx.doi.org/10.5493/wjem.v7.i1.25

INTRODUCTION

Statins remain the cornerstone therapy for primary and secondary cardiovascular prevention, mainly due to their ability to reduce low-density lipoprotein cholesterol (LDL-C). Nevertheless, a notable cardiovascular risk remains in statin-treated individuals, which has been attributed to other residual factors, such as hypertension, diet and adherence to therapy. Recently, the so called “statin escape” phenomenon has been reported as an independent cardiovascular risk factor in patients with acute myocardial infarction on prolonged statin treatment. This phenomenon was first described in small studies including patients with familial hypercholesterolemia and afterwards in the Expanded Clinical Evaluation of Lovastatin (EXCEL) study. The latter reported an increase in LDL-C levels after the first year of statin treatment, despite a marked decrease in those levels 1 mo after treatment initiation. So far there have been few reports on this phenomenon and its underlying mechanisms remain obscure.

The aim of this study was to provide additional data on the possible statin escape phenomenon based on the experience of a lipid clinic and try to elucidate potential risk factors.

MATERIALS AND METHODS

This was a retrospective (from 1999 to 2013) observational study as previously described. Briefly, dyslipidemic adults followed-up for ≥ 3 years in the Outpatient Lipid Clinic of the University Hospital of Ioannina in Greece were included. A complete assessment of serum lipid profile along with cardiovascular risk factors and concomitant treatment was available. The study protocol was approved by the Institutional Ethics Committee.

Demographic characteristics as well as various clinical and laboratory data were recorded at the baseline visit, at 6 mo and the most recent visit. These included: (1) age, gender, and smoking status; (2) body mass index (BMI) and waist circumference; (3) fasting glucose levels and glycated hemoglobin (HbA1c); (4) blood pressure (BP); (5) estimated glomerular filtration rate (MDRD - eGFR); and (6) a complete fasting lipid profile, including total cholesterol (TCHOL), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C). The methods of blood sample collection and biochemical assessments have been previously described.

The evaluation of adherence to medication was based on the Hellenic national e-prescription web database. Subjects were classified according to their compliance with treatment as good or poor compliers if they refill ≥ or < 80% of their expected prescriptions over time, respectively. We excluded those individuals meeting one of the following criteria: Use of statin therapy at baseline visit, discontinuation of statin treatment at most recent visit, change in statin treatment during follow-up and poor compliance to treatment. Statin escape phenomenon was defined as an increase in subject LDL-C levels at the most recent visit by > 10% compared with the value at 6 mo following initiation of statin therapy.

Statistical analysis

Continuous variables were tested for normality by the Kolmogorov-Smirnov test and logarithmic transformations were performed if necessary. Data are presented as mean ± standard deviation (SD) and median [interquartile range (IQR)] for normal and non-normal distributed data, respectively. χ² tests were performed for categorical values. The difference of variables between ≥ 2 groups was assessed by analysis of variance (ANOVA) and post hoc least significant difference tests were used for the comparison of variables or ratios of interest between the groups. Paired sample t tests were performed to assess the change of variables within each study group. Analysis of covariance (ANCOVA) was performed to assess the difference of variables between 2 subject groups, after adjusting for their baseline values. Binary logistic regression was performed to elucidate potential predictors for statin escape phenomenon. Two tailed significance was defined as P < 0.05. Analyses were performed with the Statistical Package for Social Sciences (SPSS), v21.0 software (SPSS IBM Corporation, Armonk, New York, United States).

RESULTS

Of 1240 hyperlipidemic individuals, 181 were considered eligible for the present analysis (Figure 1). Study participant baseline characteristics are shown in Table 1. Of 181 eligible subjects, 56 (31%) exhibited the statin escape...
phenomenon and 125 (69%) did not. There were no differences between these 2 groups apart from the higher baseline prevalence of coronary heart disease noticed in the escape group (7% vs 1%, P < 0.05). As shown in Table 1, there was no difference between the 2 groups regarding statin treatment. No participant received any non-statin lipid-lowering therapy (i.e., fibrate, ezetimibe). In addition, no difference was found regarding drugs interfering with cholesterol or statin metabolism (i.e., β-blockers, thiazides, pioglitazone, atypical antipsychotics, levotheroxyline, clopidogrel or proton-pump inhibitors; Table 1).

Baseline lipid and metabolic profile did not differ between the 2 study groups (Table 2). Six months after the initiation of statin treatment, LDL-C levels were lower in the escape compared with the non-escape group [88 (78-97) mg/dL vs 109 (91-129) mg/dL, P < 0.01; Figure 2]. On the contrary, LDL-C levels at the most recent visit were lower in the latter group [103 (96-118) mg/dL vs 94 (79-114) mg/dL, P < 0.01; Figure 2]. Similarly, non-HDL-C levels were lower six months after the initiation of statin therapy in the escape compared with the non-escape group among non-diabetic individuals [107 (97-121) mg/dL vs 132 (115-153) mg/dL, P < 0.01; Table 2]. On the other hand, higher non-HDL-C levels were noticed in the former group at the most recent visit (Table 2). TRG significantly declined by 11% and 18% in the escape and non-escape group during follow-up, respectively (P < 0.01 respectively for the change within each group; Table 2). Despite the fact, that the non-escape group exhibited higher TRG levels than the escape group 6 mo after the initiation of statin therapy [104 (83-140) mg/dL vs 97 (69-117) mg/dL, P < 0.05], there was no difference between 2 groups regarding TRG levels at the most recent visit and the change of TRG levels during follow-up (P = NS for the comparison between 2 groups). On the other hand, HDL-C levels did not change during follow-up and were not different between 2 groups (Table 2).

There was no significant difference between the 2 groups regarding BMI change. As also shown in Table 2, glucose levels did not change during follow-up and were not different between the 2 groups. eGFR declined by 0.5 and 4.1 ml/min per 1.73 m² in the escape and non-escape group, respectively (P < 0.05 respectively for the change within each group), but the difference between the 2 groups was not significant. The same was true for the change in diabetics’ HbA1c levels (Table 2, P = NS for the comparison between the 2 groups).

Binary logistic regression assessing baseline characteristics along with the changes in BMI, eGFR or HbA1c levels during follow-up did not reveal any significant predictor for the statin escape phenomenon.

During a median follow-up of 4 years, 1 of 56 escape individuals and 6 of 125 non-escape subjects were diagnosed with incident cardiovascular disease (P = NS for the comparison between the 2 groups).

**DISCUSSION**

The present report confirms the existence of statin escape phenomenon in clinical practice.

Two small studies including patients with familial hypercholesterolemia were the first to notice a paradox rebound cholesterol increase following statin dose...

---

**Table 1 Baseline characteristics of study participants**

| Variable                                | Escape group | Non-escape group |
|-----------------------------------------|--------------|------------------|
| n                                       | 56           | 125              |
| Gender (male), %                        | 43           | 52               |
| Current smoking, %                      | 9            | 14               |
| Age, yr                                 | 56 (51-63)   | 57 (49-65)       |
| Waist, cm                               | 97 (90-101)  | 98 (90-105)      |
| SBP, mmHg                               | 134 (127-146)| 140 (129-150)    |
| DBP, mmHg                               | 83 (79-95)   | 87 (80-92)       |
| Follow-up, yr                           | 4 (3-6)      | 4 (4-7)          |
| Metabolic syndrome, %                   | 39           | 40               |
| Hypertension, %                         | 59           | 57               |
| Diabetes, %                             | 11           | 9                |
| Stroke, %                               | 5            | 4                |
| Coronary heart disease, %               | 7            | 1*               |
| Abdominal aortic aneurysm, %            | 2            | 0                |
| Carotid stenosis ≥ 50%, %               | 0            | 2                |
| Peripheral arterial disease, %          | 0            | 1                |
| Statin therapy and median dose, % (median dose) |         |                  |
| Atorvastatin                            | 38 (20 mg)   | 34 (20 mg)       |
| Rosuvastatin                            | 29 (10 mg)   | 24 (10 mg)       |
| Simvastatin                             | 21 (40 mg)   | 26 (40 mg)       |
| Fluvastatin                             | 7 (80 mg)    | 6 (80 mg)        |
| Pravastatin                             | 0            | 1 (40 mg)        |
| β-blocker, %                            | 9            | 7                |
| Thiazides, %                            | 11           | 19               |
| Pioglitazone, %                         | 4            | 1                |
| Antipsychotics, %                       | 0            | 1                |
| Levothyroxine, %                        | 4            | 5                |
| Clopidogrel, %                          | 2            | 2                |
| Protons-pump inhibitors, %              | 4            | 4                |

Median follow-up duration = 4 years (IQR: 3-6 years). Values are expressed as median (IQR), unless percentages as shown. *P* < 0.05 for the comparison with the escape group. DBP: Diastolic blood pressure; IQR: Interquartile range; SBP: Systolic blood pressure.
Since then, the EXCEL study along with others, have described this so called statin escape phenomenon\textsuperscript{[3,5-7]}. Our results showing an initial marked LDL-C reduction but followed by a > 10% LDL-C increase after prolonged statin treatment in subjects exhibiting the statin escape phenomenon are in line with the results of these studies\textsuperscript{[3,5,7]}. Similar to previous studies, we did not find any predictors for this phenomenon\textsuperscript{[3,5,7]}. A recent study showed that statin escape phenomenon not only exists, but also might be an independent predictor of cardiovascular disease\textsuperscript{[3]}. The mechanisms attributing to the statin escape phenomenon have not yet been elucidated. The failure of statin therapy to decrease LDL-C levels on a long-term basis may be attributed to poor compliance with lipid-lowering treatment and diet. Particularly, an increased intake of cholesterol in the diet may contribute to intermittent variations in cholesterol levels. In addition, weight changes or a poor glycemic control may play a role.

| Table 2 Lipid and metabolic profile of study participants |
|-----------------------------------------------------------|
| **Baseline visit** | **Visit at 6 mo** | **Most recent visit** |
|---------------------|-------------------|----------------------|
| **TCHOL, mg/dL**    | 258 (233-283)     | 162 (147-174)        | 182 (170-201) |
| Escape group        |                   |                      |               |
| Non-escape group    |                   |                      |               |
| TG, mg/dL           | 259 (235-295)     | 184 (162-206)        | 172 (154-193) |
| Escape group        | 117 (89-175)      | 97 (69-117)          | 104 (87-129) |
| Non-escape group    | 132 (99-181)      | 104 (85-140)         | 108 (79-130) |
| HDL-C, mg/dL        | 53 (47-68)        | 55 (43-64)           | 54 (48-68)   |
| Escape group        |                   |                      |               |
| Non-escape group    | 53 (46-65)        | 52 (44-60)           | 56 (46-62)   |
| LDL-C, mg/dL        | 174 (152-189)     | 88 (78-97)           | 103 (96-118) |
| Escape group        |                    |                      |               |
| Non-escape group    | 177 (152-205)     | 109 (91-129)         | 94 (79-114)  |
| Non-HDL-C, mg/dL\textsuperscript{a} | 204 (181-223) | 107 (97-121) | 127 (116-143) |
| Escape group        |                    |                      |               |
| Non-escape group    | 209 (182-241)     | 132 (115-153)        | 118 (102-137) |
| BMI, kg/m\textsuperscript{2} | 27.3 (23.5-29.9) | 27.2 (23.5-30.1) | 27.6 (24-30.2) |
| Escape group        |                    |                      |               |
| Non-escape group    | 27.9 (25.5-30.6)  | 28.3 (25.1-30.9)     | 28.4 (25.5-31.5) |
| Fasting glucose, mg/dL | 95 (88-105)  | 95 (87-129)          | 95 (88-106)  |
| Escape group        |                    |                      |               |
| Non-escape group    | 93 (87-103)       | 94 (88-104)          | 96 (89-106)  |
| HbA1c, %\textsuperscript{a,2} | 8.5 (7.7-8.6)  | 6.6 (5.6-5.9)        | 6.7 (6.6-7.1) |
| Escape group        |                    |                      |               |
| Non-escape group    | 8.4 (7.7-10.9)    | 6.7 (6.3-7.9)        | 6.9 (6.3-7.6) |
| MDRD-eGFR, ml/min per 1.73 m\textsuperscript{2} | 77 (69.6-86.7)  | 76.6 (67.9-84.8)     | 76.5 (65.4-81) |
| Escape group        |                    |                      |               |
| Non-escape group    | 81 (70.7-91.4)    | 79.7 (69.89.7)       | 76.9 (65.5-85.7) |

Values are expressed as median (IQR). To convert from mg/dL to mmol/L multiply by 0.0555 for glucose, 0.02586 for TC, HDL-C, LDL-C, and 0.01129 for TG. \textsuperscript{a}Non-HDL-C levels refer to non-diabetic individuals (n = 164); \textsuperscript{b}HbA1c values refer to diabetic individuals (n = 17). \textsuperscript{a}P < 0.05 for the comparison with the escape group. BMI: Body mass index; MDRD-eGFR: Estimated glomerular filtration rate according to The Modification of Diet in Renal Disease (MDRD) Study equation; HbA1c: Glycated hemoglobin; HDL-C: High-density lipoprotein cholesterol; IQR: Interquartile range; LDL-C: Low-density lipoprotein cholesterol; non-HDL-C: Non-high-density lipoprotein cholesterol; TCHOL: Total cholesterol; TG: Triglycerides.

![Figure 2 Change in low-density lipoprotein cholesterol levels during follow-up. \textsuperscript{b}P < 0.05 for the comparison between the 2 groups. LDL-C: Low-density lipoprotein cholesterol.](image-url)
control in diabetic individuals could also cause a LDL-C increase, which could be wrongly considered as statin escape phenomenon. After excluding subjects with these characteristics, one study concluded that only 1.2% of 161 study participants exhibited the statin escape phenomenon, although 28% of those were initially considered to meet the criteria of statin escape. Despite the fact that no data regarding diet and exercise was available in our study, there was no significant difference between groups in terms of BMI change, glycemic control and kidney function.

We also assessed non-HDL-C levels in non-diabetic individuals considering that atherogenic dyslipidemia may alter LDL-C changes\(^3\). Statin escapers had higher non-HDL-C levels after prolonged statin therapy in comparison with non-escapers, although they had a higher non-HDL-C reduction 6 mo after treatment onset. Although we checked for adherence to therapy, our study might have included non-compliant individuals. It may be possible that the escapers adhered less to statin therapy and diet after seeing a large drop in their LDL-C levels. Another possible explanation for the statin escape phenomenon could be the concomitant therapy, since a variety of drugs could increase LDL-C lowering action of statins by inducing cytochromes CYP450-3A4 and 2C9\(^13,14\). According to a few experimental studies, statin escape phenomenon could be attributed to a slow increase in the 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity or to an increase in proprotein convertase subtilisin kexin-like 9 (PCSK9) levels caused by prolonged statin therapy\(^15-19\).

Our data suggest that statin escape phenomenon is indeed noticed in clinical practice, although its clinical significance remains uncertain. Patients with larger than anticipated initial LDL-C lowering should be carefully monitored.

**REFERENCES**

1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Ageewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J.* 2011; 32: 1769-1818 [PMID: 21712404 DOI: 10.1093/eurheartj/ehr138]

2. Mora S, Wenger NK, Demico DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation* 2012; 125: 1979-1987 [PMID: 22461416 DOI: 10.1161/CIRCULATIONAHA.111.088591]

3. Ota T, Ishii H, Suzuki S, Shibata Y, Taniyama Y, Harata S, Shimbo Y, Takayama Y, Tanaka A, Kawamura Y, Ougi N, Maeda K, Kondo T, Murohara T. Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS). *Atherosclerosis* 2015; 242: 155-160 [PMID: 26188539 DOI: 10.1016/j.atherosclerosis.2015.07.012]

4. Ilingworth DR, Sexton GJ. Hypocholesterolemic effects of mevulin in patients with heterozygous familial hypercholesterolemia. *J Clin Invest* 1984; 74: 1972-1978 [PMID: 6569064 DOI: 10.1172/JCI111618]

5. Yamamoto A, Yokoyama S, Yamamura T. Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia. *Atherosclerosis* 1988; 71: 257-260 [PMID: 3135813]

6. Bradford RH, Shear CL, Chremos AN, Franklin FA, Nash DT, Hurley DP, Djouvé CA, Pool JL, Schnaper H, Hesney M. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. *Am J Med* 1991; 91: 188-245 [PMID: 1867322]

7. Yeshurun D, Slobodin G, Keren D, Elias N. Statin escape phenomenon: Does it really exist? *Eur J Intern Med* 2005; 16: 192-194 [PMID: 15967335 DOI: 10.1016/j.ejim.2004.11.007]

8. Rubinstein A, Weintraub M. Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment. *Am J Cardiol* 1995; 76: 184-186 [PMID: 7611599]

9. Ugawa T, Kaka A, Moritani H, Shikama H. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. *Br J Pharmacol* 2002; 135: 1572-1578 [PMID: 11906972 DOI: 10.1038/sj.bjp.0704595]

10. Barkas F, Elias M, Liberopoulos E, Liotontos A, Rizos EC. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. *Atherosclerosis* 2016; 247: 58-63 [PMID: 26686509 DOI: 10.1016/j.atherosclerosis.2016.02.001]

11. Barkas F, Milionis H, Kostapanos MS, Mikhailidis DP, Elias M, Liberopoulos E. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. *Curr Med Res Opin* 2015; 31: 221-228 [PMID: 25418708 DOI: 10.1185/03007965.2014.982751]

**COMMENTS**

**Background**

A few studies have reported on the so called “statin escape phenomenon”, which describes an increase in low-density lipoprotein cholesterol (LDL-C) levels after prolonged statin therapy despite an initial marked decrease. Statin escape phenomenon has been recently reported as an independent cardiovascular risk factor.

**Research frontiers**

Very few studies have reported on statin escape phenomenon and its underlying mechanisms remain obscure. The present study contributes to clarifying whether this phenomenon exists in clinical practice.

**Innovations and breakthroughs**

This was a retrospective observational study with a small sample size. However, only the EXCEL study, which is the only randomized trial reporting on statin escape phenomenon and a retrospective cohort had larger samples. The small number of eligible participants did not allow any analysis to identify potential predictors for the statin-escape phenomenon. Additionally, due to small sample and low incidence of cardiovascular disease this study did not have the power to establish an association between statin escape and incidence of cardiovascular disease. Nevertheless, this study confirms the limited bibliography reporting on statin escape phenomenon and its quite high prevalence (28%-31%).

**Applications**

This study suggests that further investigation on the underlying pathophysiology of the statin escape phenomenon and its potential clinical ramifications is required.

**Peer-review**

This study is well written and the patients have been well selected although several variables could have influenced the results.
Barkas F et al. Statin escape phenomenon: Fact or fiction?

12 Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol 2016; 10: 306-313 [PMID: 27055961 DOI: 10.1016/j.jacl.2015.11.015]

13 Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010; 10: 11-28 [PMID: 20104931 DOI: 10.2165/13168600-000000000-00000]

14 Barkas F, Liberopoulos E, Kostapanos M, Rizos C, Klouras E, Elisaf M. Proton pump inhibitors and statins: a combination that favors LDL-c reduction? Atherosclerosis 2015; 241: e202 [DOI: 10.1016/j.atherosclerosis.2015.04.973]

15 Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995; 1254: 7-12 [PMID: 7811749]

16 Fujioka T, Tsujita Y. Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats. Eur J Pharmacol 1997; 323: 223-228 [PMID: 9128842]

17 Stone BG, Evans CD, Prigge WF, Duane WC, Gebhard RL. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J Lipid Res 1989; 30: 1943-1952 [PMID: 2621421]

18 Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbiikay M, Ooi TC, Chrétien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008; 7: 22 [PMID: 18547436 DOI: 10.1186/1476-511X-7-22]

19 Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-398 [PMID: 18033751 DOI: 10.1194/jlr.M700437-JLR200]

P- Reviewer: Corso G, Mihaila RG  S- Editor: Ji FF  L- Editor: A
E- Editor: Lu YJ
